Longevity
Screen for 50+ cancers before symptoms show1
Add the Galleri® multi-cancer early detection test to your Longevity program. Now available in Ontario. Coming soon to BC.
- 7X Nearly 7X more cancers found alongside routine screening.2*
- 70% Galleri’s detection rate for a group of 12 deadly cancers.2§
- 53% 53% were caught at stage I or II, when cure is most possible.2
How the Galleri multi-cancer early detection test works
-
Every cell leaves DNA behind3
Cells shed fragments of DNA into your blood as they turn over. The fragments that come from cancer carry different methylation patterns and that difference is what makes them findable.
-
The test reads the pattern1,3
Two small tubes of blood are enough. The Galleri test reads the methylation patterns across those fragments, looking for a pattern shared by more than 50 types of cancer.
-
Signals predict cancer origin4
Finding a signal is only half of it. The test also predicts the tissue or organ it most likely came from, so your practitioner knows where to start looking.
What it costs
Galleri costs $1,650. We know that’s a significant cost, and we want to be transparent about what goes into it.
Most of the price reflects the cost of the test itself, including the specialized analysis performed by GRAIL, the company that developed Galleri. Felix adds a modest markup to cover an at-home blood draw, review by a Felix healthcare practitioner, and support with next steps if a cancer signal is detected.
We’ve priced Galleri lower than other Canadian providers. We also know there’s more work to do to make early cancer detection broadly accessible, and we see this launch as a first step.
- Lowest price in Canada
- Free home collection
- Unlimited support
Screen for cancer before symptoms appear
Cancer can grow for a long time without causing symptoms. As it grows it sheds DNA into the blood stream, and that DNA is distinguishable from the rest. The Galleri test can pick up on that difference before cancerous symptoms tend to appear.1,3
A clear picture of your results, and support every step of the way
-
No Cancer Signal Detected
About 99 in 100 people get this result.2 Keep up with the routine screening your practitioner recommends, retest next year, and reach out to your Felix healthcare practitioner any time you need support.
-
Cancer Signal Detected
This result comes back for roughly 1 in 100 people.2 It means cancer-associated DNA was found in your sample, along with a prediction of where in the body it came from. Since follow-up testing is needed to confirm whether cancer is present, your Felix healthcare practitioner will arrange a follow-up to discuss next steps.
Comprehensive testing made simple
-
Step 1
Answer a few questions
about your health
-
Step 2
Complete your lab work
from home
-
Step 3
Get detailed results
and clear next steps
Frequently asked questions
The Galleri multi-cancer early detection test screens for a signal associated with more than 50 types of cancer from a single blood draw.¹ A cancer signal detected result does not diagnose cancer on its own, but it can indicate that follow-up diagnostic evaluation is warranted.
This add-on is designed for patients who want a proactive, multi-cancer early detection test alongside their broader health data. It can be a useful option for adults who want to add more visibility beyond standard screening pathways, especially for cancers that do not have routine screening tests today. Galleri is available with a requisition only, through your Felix healthcare practitioner.
Results are reported through your Felix account. There are two possible test results, No Cancer Signal Detected result or a Cancer Signal Detected result. If a signal is detected, the report will also indicate the most likely tissue of origin to help guide next steps with your care team.
The Galleri multi-cancer test can be taken annually as part of an ongoing proactive screening strategy.
No, the Galleri multi-cancer early detection test is not diagnostic. If a cancer signal is detected, further diagnostic testing in person is needed to confirm cancer. The test does not detect a signal for all cancers, and not all cancers can be detected in the blood. False positive and false negative results do occur. We recommend talking to your healthcare provider to determine if additional testing is needed.
References
- 1 Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167–77. doi:10.1016/j.annonc.2021.05.806
-
2
Giridhar KV, et al. Safety and performance results from PATHFINDER 2 (PF2), a registrational study of a multi-cancer early detection (MCED) test in an intended-use population [presentation]. ASCO Annual Meeting; 2026 May 31; Chicago. asco.org/abstracts-presentations/260912
*Includes screening in the US for breast, cervical, colorectal, and lung cancers.
§ 12-month episode sensitivity was 69.8% for a prespecified group of 12 cancer types responsible for approximately two-thirds of U.S. cancer deaths, including anus, bladder, colon/rectum, esophagus, head and neck, liver/bile duct, lung, lymphoma, ovary, pancreas, plasma cell neoplasm, and stomach. - 3 Liu MC, Oxnard GR, Klein EA, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745–59. doi:10.1016/j.annonc.2020.02.011
- 4 Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multi-cancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402:1251–60. doi:10.1016/S0140-6736(23)01700-2
- 5 Canadian Cancer Society. Cancer statistics at a glance. cancer.ca/en/research/cancer-statistics/cancer-statistics-at-a-glance
- 6 American Association for Cancer Research. Cancer progress report 2023. cancerprogressreport.aacr.org/progress/
Important safety information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment. Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer. If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only. For more information, please refer to our Privacy Policy.
Laboratory and Test Information
The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. This test is not Health Canada approved, and has not been endorsed by any professional medical societies at this time. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
Trademark
Galleri is a registered trademark of GRAIL, Inc.